Company Encyclopedia
View More
name
Oncolytics Biotech
ONCY.US
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc.
1.946 T
ONCY.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Oncolytics Biotech® Provides Update On Special Meeting Of Shareholders

    Nov 20 (Reuters) - Oncolytics Biotech Inc:* ONCOLYTICS BIOTECH® PROVIDES UPDATE ON SPECIAL MEETING OF SHAREHOLDERS* ONCOLYTICS BIOTECH INC - CANCELS AND WILL RESCHEDULE SPECIAL SHAREHOLDER MEETING* ONCOLYTICS BIOTECH INC - SPECIAL MEETING RESCHEDULED DUE TO U.S. GOVERNMENT SHUTDOWN Source text: Further company coverage:

    Reuters·
    US
    ONCY
    +8.19%
    Reuters·
    US
    ONCY
    +8.19%

    Oncolytics Biotech Plans Move from Alberta to Nevada

    Oncolytics Biotech Inc., a clinical-stage immunotherapy company, plans to move its jurisdiction from Alberta, Canada to Nevada, USA. A special shareholder meeting to vote on this reorganization was postponed due to U.S. SEC delays caused by a federal government shutdown. The meeting will be rescheduled soon. This information was originally published by Oncolytics Biotech via Business Wire.

    Reuters·
    US
    ONCY
    +8.19%
    Reuters·
    US
    ONCY
    +8.19%

    Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital

    RBC Capital analyst Douglas Miehm maintained a Buy rating on Oncolytics Biotech with a price target of $3.50. Miehm is a 3-star analyst with a 3.9% average return and a 47.97% success rate. H.C. Wainwright’s Patrick Trucchio also issued a Buy rating, while JonesTrading maintained a Hold rating on the stock.

    Tip Ranks·
    US
    ONCY
    +8.19%
    Tip Ranks·
    US
    ONCY
    +8.19%

    BUZZ-Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial

    Oncolytics Biotech's shares rose 5.7% after the U.S. FDA approved the design for a clinical trial of pelareorep in advanced pancreatic cancer. The trial will compare chemotherapy alone versus chemotherapy plus pelareorep, with an option to add a checkpoint inhibitor. Pelareorep has shown promise in previous studies and has FDA Fast Track status.

    Reuters·
    US
    ONCY
    +8.19%
    Reuters·
    US
    ONCY
    +8.19%

    Oncolytics Biotech® Aligns With FDA On Pivotal Study Design For Pelareorep In First-Line Pancreatic Cancer

    Oncolytics Biotech Inc :ONCOLYTICS BIOTECH® ALIGNS WITH FDA ON PIVOTAL STUDY DESIGN FOR PELAREOREP IN FIRST-LINE PANCREATIC CANCERONCOLYTICS BIOTECH INC - TO LAUNCH IMMUNOTHERAPY TRIAL IN PANCREATIC CANCER IN 2026

    Reuters·
    US
    ONCY
    +8.19%
    Reuters·
    US
    ONCY
    +8.19%
    © 2025 Longbridge｜Disclaimer